Evidence map›Paper›PMID 31427566›Full record

ArticleCell death & disease2019

Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production.

Jiajun Fan, Xuyao Zhang, Shaofei Wang, Wei Chen, Yubin Li, Xian Zeng, Yichen Wang, Jingyun Luan, Li Li, Ziyu Wang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Sex-Specific Alterations in Cardiac DNA Methylation in Adult Mice by Perinatal Lead Exposure.International journal of environmental research and public health · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Jiajun FanMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China.
Xuyao ZhangMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China.ORCID http://orcid.org/0000-0003-1654-5550
Shaofei WangMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China.
Wei ChenMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China.
Yubin LiMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China.
Xian ZengMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China.
Yichen WangMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China.
Jingyun LuanMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China.
Li LiDepartment of Microbiological and Biochemical Pharmacy and The Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Ziyu WangDepartment of Microbiological and Biochemical Pharmacy and The Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Xilin SunThe Fourth Hospital of Harbin Medical University, Harbin, 150028, P. R. China. sunxl@ems.hrbmu.edu.cn.
Baozhong ShenThe Fourth Hospital of Harbin Medical University, Harbin, 150028, P. R. China. shenbz@ems.hrbmu.edu.cn.
Dianwen JuMinhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China. dianwenju@fudan.edu.cn.
Fudan University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD), which comprises over 50% of all cases of non-small-cell lung cancer, has a poor prognosis and requires novel therapeutic approaches. The sonic Hedgehog (Shh) pathway, which plays a crucial role in differentiation, proliferation, and survival of cancer cells, is likely to be activated in LUADs, suggesting the Shh pathway as a potential therapeutic target for LUAD treatment. In this study, we reported that vismodegib, an inhibitor of the Shh pathway, only elicited minor antitumor efficacy in A549 and NCI-H1975 LUAD cells as well as in the xenograft tumors, with overexpressed GLI2 and increased autophagic activity. The aberrant autophagy in LUAD cells was further confirmed by the three main stages of autophagic flux, including the formation of autophagosomes, the fusion of autophagosomes with lysosomes, and degradation of autophagosomes in lysosomes. Furthermore, inhibition of autophagy by siRNA against ATG5 or ATG7 rescued the sensitivity of A549 and NCI-H1975 LUAD cells to vismodegib in vitro. Meanwhile, administration of the pharmaceutical inhibitor of autophagy, chloroquine, contributed to the enhanced anti-LUAD efficacy of vismodegib in vivo, probably through overproduction of ROS, acceleration of apoptosis, and suppression of GLI2 in LUAD tissues. In summary, our research revealed that downregulating autophagy facilitated the anti-LUAD efficacy of the Shh pathway suppression, thus highlighting a potential approach for LUAD therapy via simultaneously targeting the Shh signaling and autophagy pathway.

Indexed as

A549 CellsAdenocarcinoma of LungAnilidesAnimalsAutophagyCell Line, TumorDown-RegulationDrug Resistance, NeoplasmHedgehog ProteinsHeterograftsHumansLung NeoplasmsMaleMiceMice, Inbred BALB CMice, NudeAnilidesGLI2 protein, humanHedgehog ProteinsHhAntag691Nuclear ProteinsPyridinesReactive Oxygen SpeciesSHH protein, humanZinc Finger Protein Gli2

Identifiers

PMID31427566
PMCPMC6700102
OpenAlexW2969710316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.